Literature DB >> 26194981

Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.

Vinod Kumar1, Raja Ramachandran1, Ashwani Kumar2, Ritambhra Nada2, Deepti Suri3, Anju Gupta3, Harbir Singh Kohli1, Krishan Lal Gupta1, Vivekanand Jha1,4.   

Abstract

Idiopathic membranous nephropathy (IMN), the commonest cause of adult nephrotic syndrome (NS), accounts for only a minority of paediatric NS. Antibodies to m-type phospholipase A2 receptor (PLA2R) are seen in two-thirds of adult IMN cases. PLA2R staining in glomerular deposits is observed in 74% and 45% of adult and paediatric IMN cases, respectively. However, there are no reports of anti-PLA2R in paediatric IMN. We evaluated anti-PLA2R levels and PLA2R in gloemrular deposits in paediatric IMN seen at our center. Five cases were enrolled, all the cases stained for PLA2R in glomeruli and three (60%) had antibodies to PLA2R antigen. There was a parellel reduction in proteinuria and anti-PLA2R titer. The present report suggests that PLA2R has a contributory role in the pathogenesis of paediatric IMN.
© 2015 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  glomerulonephritis; membranous nephropathy; nephrotic syndrome; tacrolimus

Mesh:

Substances:

Year:  2015        PMID: 26194981     DOI: 10.1111/nep.12478

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  11 in total

1.  Proteinuria in a patient with Graves' disease: Questions.

Authors:  Aydilek Dagdeviren Cakir; Nur Canpolat; Seha Saygili; Isin Kilicaslan; Hande Turan; Oya Ercan; Olcay Evliyaoglu
Journal:  Pediatr Nephrol       Date:  2019-03-06       Impact factor: 3.714

2.  Proteinuria in a patient with Graves' disease: Answers.

Authors:  Aydilek Dagdeviren Cakir; Nur Canpolat; Seha Saygili; Isin Kilicaslan; Hande Turan; Oya Ercan; Olcay Evliyaoglu
Journal:  Pediatr Nephrol       Date:  2019-03-06       Impact factor: 3.714

3.  M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy.

Authors:  Shoichiro Kanda; Shigeru Horita; Takeshi Yanagihara; Akira Shimizu; Motoshi Hattori
Journal:  Pediatr Nephrol       Date:  2016-12-05       Impact factor: 3.714

Review 4.  Primary Membranous Nephropathy.

Authors:  William G Couser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

5.  Profile of Indian Patients With Membranous Nephropathy.

Authors:  Priyadarsani Subramanian; Hemanth Kumar; Bipin Tiwari; Adarsh Barwad; Soumita Bagchi; Arvind Bagga; Sanjay Kumar Agarwal; Amit Kumar Dinda; Geetika Singh
Journal:  Kidney Int Rep       Date:  2020-07-02

6.  Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.

Authors:  Rossana Malatesta-Muncher; Karen W Eldin; Laurence H Beck; Mini Michael
Journal:  Pediatr Nephrol       Date:  2018-03-15       Impact factor: 3.714

7.  Screening and Analysis of Key Genes in miRNA-mRNA Regulatory Network of Membranous Nephropathy.

Authors:  Yawei Hou; Yameng Li; Yichuan Wang; Wenpu Li; Zhenwei Xiao
Journal:  J Healthc Eng       Date:  2021-11-16       Impact factor: 2.682

8.  Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing.

Authors:  Yawei Hou; Yameng Li; Wenpu Li; Zhenwei Xiao
Journal:  Comput Math Methods Med       Date:  2022-04-14       Impact factor: 2.809

Review 9.  Pediatric membranous nephropathy: In the novel antigens era.

Authors:  Guoping Huang; Fei Liu; Ling Yu; Jingjing Wang; Junyi Chen; Jianhua Mao
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

10.  Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.

Authors:  Giuseppe Stefano Netti; Barbara Infante; Federica Spadaccino; Giulia Godeas; Maria Grazia Corallo; Concetta Prisciandaro; Laura Croce; Mario Rotondi; Loreto Gesualdo; Giovanni Stallone; Giuseppe Grandaliano; Elena Ranieri
Journal:  J Immunol Res       Date:  2019-11-05       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.